HK1207369A1 - -苯氧基- -嘧啶- -酮衍生物及其用作 逆轉錄酶抑制劑 - Google Patents

-苯氧基- -嘧啶- -酮衍生物及其用作 逆轉錄酶抑制劑

Info

Publication number
HK1207369A1
HK1207369A1 HK15107948.1A HK15107948A HK1207369A1 HK 1207369 A1 HK1207369 A1 HK 1207369A1 HK 15107948 A HK15107948 A HK 15107948A HK 1207369 A1 HK1207369 A1 HK 1207369A1
Authority
HK
Hong Kong
Prior art keywords
hiv
pyrimidin
phenoxy
derivatives
reverse transcriptase
Prior art date
Application number
HK15107948.1A
Other languages
English (en)
Inventor
Kenneth L Arrington
Christopher Burgey
Robert Gilfillan
Yongxin Han
Mehul Patel
Chun Sing Li
Yaozong Li
Yunfu Luo
Jiayi Xu
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of HK1207369A1 publication Critical patent/HK1207369A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/56—One oxygen atom and one sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Enzymes And Modification Thereof (AREA)
HK15107948.1A 2012-10-08 2015-08-18 -苯氧基- -嘧啶- -酮衍生物及其用作 逆轉錄酶抑制劑 HK1207369A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2012001358 2012-10-08
PCT/US2013/063612 WO2014058747A1 (en) 2012-10-08 2013-10-07 5-phenoxy-3h-pyrimidin-4-one derivatives and their use as hiv reverse transcriptase inhibitors

Publications (1)

Publication Number Publication Date
HK1207369A1 true HK1207369A1 (zh) 2016-01-29

Family

ID=49354986

Family Applications (2)

Application Number Title Priority Date Filing Date
HK15107948.1A HK1207369A1 (zh) 2012-10-08 2015-08-18 -苯氧基- -嘧啶- -酮衍生物及其用作 逆轉錄酶抑制劑
HK18112148.6A HK1252786A1 (zh) 2012-10-08 2018-09-20 包含5-苯氧基-3h-嘧啶-4-酮衍生物的組合物及其用於預防或治療hiv感染的方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
HK18112148.6A HK1252786A1 (zh) 2012-10-08 2018-09-20 包含5-苯氧基-3h-嘧啶-4-酮衍生物的組合物及其用於預防或治療hiv感染的方法

Country Status (47)

Country Link
US (3) US9469634B2 (zh)
EP (3) EP2903977B1 (zh)
JP (2) JP5877281B2 (zh)
KR (1) KR101696128B1 (zh)
CN (1) CN104822670B (zh)
AP (1) AP2015008355A0 (zh)
AR (1) AR092876A1 (zh)
AU (1) AU2013329552B8 (zh)
BR (1) BR112015007742B8 (zh)
CA (1) CA2887312C (zh)
CL (1) CL2015000880A1 (zh)
CO (1) CO7350655A2 (zh)
CR (1) CR20150183A (zh)
CY (3) CY1119655T1 (zh)
DK (3) DK3656384T3 (zh)
DO (1) DOP2015000082A (zh)
EA (1) EA033436B1 (zh)
EC (1) ECSP15018618A (zh)
ES (3) ES2770774T3 (zh)
GE (1) GEP20186838B (zh)
GT (1) GT201500088A (zh)
HK (2) HK1207369A1 (zh)
HR (3) HRP20220502T1 (zh)
HU (3) HUE037231T2 (zh)
IL (1) IL238090B (zh)
JO (1) JO3470B1 (zh)
LT (3) LT3656384T (zh)
MA (1) MA37959A2 (zh)
MD (1) MD4625C1 (zh)
ME (1) ME02918B (zh)
MX (1) MX355040B (zh)
MY (1) MY192716A (zh)
NI (1) NI201500048A (zh)
NO (1) NO2903977T3 (zh)
NZ (1) NZ706729A (zh)
PE (1) PE20151787A1 (zh)
PH (1) PH12015500764A1 (zh)
PL (3) PL3295942T3 (zh)
PT (3) PT3295942T (zh)
RS (3) RS63112B1 (zh)
SG (1) SG11201502620UA (zh)
SI (3) SI3656384T1 (zh)
TN (1) TN2015000106A1 (zh)
TW (2) TWI598343B (zh)
UA (1) UA114006C2 (zh)
WO (1) WO2014058747A1 (zh)
ZA (1) ZA201503143B (zh)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012048113A2 (en) 2010-10-07 2012-04-12 The General Hospital Corporation Biomarkers of cancer
JO3470B1 (ar) 2012-10-08 2020-07-05 Merck Sharp & Dohme مشتقات 5- فينوكسي-3h-بيريميدين-4-أون واستخدامها كمثبطات ناسخ عكسي ل hiv
US20160221965A1 (en) 2013-09-16 2016-08-04 Bayer Pharma Aktiengesellschaft Disubstituted trifluoromethyl pyrimidinones and their use
RU2693622C2 (ru) * 2014-04-01 2019-07-03 Мерк Шарп И Доум Корп. Пролекарственные средства ингибиторов обратной транскриптазы вич
AU2015308350B2 (en) 2014-08-29 2020-03-05 Tes Pharma S.R.L. Inhibitors of alpha-amino-beta-carboxymuconic acid semialdehyde decarboxylase
FR3027901B1 (fr) * 2014-10-31 2018-03-16 Universite De Reims Champagne Ardenne Nouveaux procedes appartenant a la famille des pyridazinones.
US10350165B2 (en) * 2014-12-12 2019-07-16 Ojai Energetics Pbc Methods and systems for forming stable droplets
IL258821B (en) 2015-10-23 2022-07-01 Harvard College Nucleobase editors and their uses
SG11201900907YA (en) 2016-08-03 2019-02-27 Harvard College Adenosine nucleobase editors and uses thereof
US11661590B2 (en) 2016-08-09 2023-05-30 President And Fellows Of Harvard College Programmable CAS9-recombinase fusion proteins and uses thereof
US11542509B2 (en) 2016-08-24 2023-01-03 President And Fellows Of Harvard College Incorporation of unnatural amino acids into proteins using base editing
GB2573062A (en) 2016-10-14 2019-10-23 Harvard College AAV delivery of nucleobase editors
WO2018119359A1 (en) 2016-12-23 2018-06-28 President And Fellows Of Harvard College Editing of ccr5 receptor gene to protect against hiv infection
EP3592853A1 (en) 2017-03-09 2020-01-15 President and Fellows of Harvard College Suppression of pain by gene editing
WO2018165629A1 (en) 2017-03-10 2018-09-13 President And Fellows Of Harvard College Cytosine to guanine base editor
CA3057192A1 (en) 2017-03-23 2018-09-27 President And Fellows Of Harvard College Nucleobase editors comprising nucleic acid programmable dna binding proteins
US11560566B2 (en) 2017-05-12 2023-01-24 President And Fellows Of Harvard College Aptazyme-embedded guide RNAs for use with CRISPR-Cas9 in genome editing and transcriptional activation
JP2020534795A (ja) 2017-07-28 2020-12-03 プレジデント アンド フェローズ オブ ハーバード カレッジ ファージによって支援される連続的進化（ｐａｃｅ）を用いて塩基編集因子を進化させるための方法および組成物
US11319532B2 (en) 2017-08-30 2022-05-03 President And Fellows Of Harvard College High efficiency base editors comprising Gam
EP3684364A4 (en) * 2017-09-18 2021-06-02 Goldfinch Bio, Inc. PYRIDAZINONE AND METHOD OF USE THEREOF
US11795443B2 (en) 2017-10-16 2023-10-24 The Broad Institute, Inc. Uses of adenosine base editors
EP4317972A3 (en) 2018-02-06 2024-03-13 The General Hospital Corporation Repeat rna as biomarkers of tumor immune response
CA3098585A1 (en) 2018-04-30 2019-11-07 Ribon Therapeutics Inc. Pyridazinones as parp7 inhibitors
EP3852533B1 (en) 2018-09-18 2024-02-28 Goldfinch Bio, Inc. Pyridazinones and methods of use thereof
JP7045528B2 (ja) * 2018-12-18 2022-03-31 メルク・シャープ・アンド・ドーム・コーポレーション Ｈｉｖに感染した細胞に対する選択的細胞毒性薬としてのピリミドン誘導体
WO2020191153A2 (en) 2019-03-19 2020-09-24 The Broad Institute, Inc. Methods and compositions for editing nucleotide sequences
KR20220011673A (ko) * 2019-05-22 2022-01-28 머크 샤프 앤드 돔 코포레이션 Hiv 감염된 세포에 대한 선택적 세포독성제로서의 피리디논 유도체
CA3156814A1 (en) * 2019-10-04 2021-04-08 Goldfinch Bio, Inc. Biomarker-based treatment of focal segmental glomerulosclerosis and diabetic kidney disease
AU2020375821A1 (en) 2019-10-30 2022-06-02 Ribon Therapeutics, Inc. Pyridazinones as PARP7 inhibitors
WO2021107066A1 (ja) 2019-11-28 2021-06-03 塩野義製薬株式会社 インテグラーゼ阻害剤及び抗ｈｉｖ薬を組み合わせることを特徴とするｈｉｖ感染症の予防及び治療用医薬
TW202146416A (zh) 2019-12-11 2021-12-16 德商拜耳廠股份有限公司 吡唑并三𠯤
KR20230019843A (ko) 2020-05-08 2023-02-09 더 브로드 인스티튜트, 인코퍼레이티드 표적 이중 가닥 뉴클레오티드 서열의 두 가닥의 동시 편집을 위한 방법 및 조성물
WO2022067130A2 (en) 2020-09-24 2022-03-31 The Broad Institute, Inc. Prime editing guide rnas, compositions thereof, and methods of using the same
WO2022150790A2 (en) 2021-01-11 2022-07-14 The Broad Institute, Inc. Prime editor variants, constructs, and methods for enhancing prime editing efficiency and precision
EP4363418A1 (en) * 2021-07-01 2024-05-08 JANSSEN Pharmaceutica NV 5-oxo-pyrido[2,3-d]pyridazin-6(5h)-yl acetamides
AU2022325166A1 (en) 2021-08-06 2024-02-08 President And Fellows Of Harvard College Improved prime editors and methods of use
WO2023076898A1 (en) 2021-10-25 2023-05-04 The Broad Institute, Inc. Methods and compositions for editing a genome with prime editing and a recombinase
WO2023102538A1 (en) 2021-12-03 2023-06-08 The Broad Institute, Inc. Self-assembling virus-like particles for delivery of prime editors and methods of making and using same
WO2023205687A1 (en) 2022-04-20 2023-10-26 The Broad Institute, Inc. Improved prime editing methods and compositions
WO2023240137A1 (en) 2022-06-08 2023-12-14 The Board Institute, Inc. Evolved cas14a1 variants, compositions, and methods of making and using same in genome editing
WO2024077267A1 (en) 2022-10-07 2024-04-11 The Broad Institute, Inc. Prime editing methods and compositions for treating triplet repeat disorders
WO2024108092A1 (en) 2022-11-17 2024-05-23 The Broad Institute, Inc. Prime editor delivery by aav

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5519021A (en) 1992-08-07 1996-05-21 Merck & Co., Inc. Benzoxazinones as inhibitors of HIV reverse transcriptase
ATE334966T1 (de) 1998-04-27 2006-08-15 Centre Nat Rech Scient 3-(amino- oder aminoalkyl)pyridinon-derivate und ihre anwendung bei der behandlung von mit hiv zusammenhängenden krankheiten
IT1305313B1 (it) 1998-07-17 2001-05-04 Colla Paolo 3,4 - diidro- 6- benzil-4-oxopirimidine sostituite e relativo processodi produzione e impiego nella terapia delle infezioni da hiv-1.
SE9904045D0 (sv) 1999-11-09 1999-11-09 Astra Ab Compounds
CA2422367C (en) 2000-09-15 2010-05-18 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
ES2598404T3 (es) 2003-02-07 2017-01-27 Janssen Pharmaceutica Nv Derivados de pirimidina para la prevención de infección por el VIH
TW200423930A (en) 2003-02-18 2004-11-16 Hoffmann La Roche Non-nucleoside reverse transcriptase inhibitors
CN100469769C (zh) * 2003-03-24 2009-03-18 弗·哈夫曼-拉罗切有限公司 作为逆转录酶抑制剂的苄基-哒嗪酮
TW200505441A (en) 2003-03-24 2005-02-16 Hoffmann La Roche Non-nucleoside reverse transcriptase inhibitorsⅠ
AU2005206511A1 (en) 2004-01-12 2005-08-04 Gilead Sciences, Inc. Pyrimidyl phosphonate antiviral compounds and methods of use
CA2559552A1 (en) 2004-03-23 2005-09-29 F. Hoffmann-La Roche Ag Benzyl-pyridazinone derivatives as non-nucleoside reverse transcriptase inhibitors
DE602005017604D1 (de) 2004-04-23 2009-12-24 Hoffmann La Roche Inhibitoren der nicht-nukleosid-inhibitoren der reversen transkriptase
US7166738B2 (en) 2004-04-23 2007-01-23 Roche Palo Alto Llc Non-nucleoside reverse transcriptase inhibitors
EP1831157A2 (en) 2004-12-22 2007-09-12 Pfizer Limited Nonnucleoside inhibitors of hiv-1 reverse transcriptase
AR057455A1 (es) 2005-07-22 2007-12-05 Merck & Co Inc Inhibidores de la transcriptasa reversa de vih y composicion farmaceutica
EP1940781A1 (en) 2005-10-19 2008-07-09 F.Hoffmann-La Roche Ag Phenyl-acetamide nnrt inhibitors
ES2320042T3 (es) 2005-10-19 2009-05-18 F. Hoffmann-La Roche Ag Inhibidores de transcriptasa reversa con nucleosidos de n-fenil fenilacetamida.
US7803940B2 (en) 2006-11-24 2010-09-28 Takeda Pharmaceutical Company Limited Heteromonocyclic compound or a salt thereof having strong antihypertensive action, insulin sensitizing activity and the like production thereof and use thereof for prophylaxis or treatment of cardiovascular diseases, metabolic diseases and/or central nervous system diseases
AU2007322608A1 (en) 2006-11-24 2008-05-29 Takeda Pharmaceutical Company Limited Heteromonocyclic compound and use thereof
TW200831085A (en) 2006-12-13 2008-08-01 Merck & Co Inc Non-nucleoside reverse transcriptase inhibitors
BRPI0820162A2 (pt) * 2007-11-20 2019-09-24 Merck Sharp & Dohme composto, composição farmacêutica, método para a profilazia ou tratamento de infecção pela hiv ou para a profilaxia, tratamento ou retardo no início da aids
EP2231621B1 (en) * 2008-01-08 2016-11-02 Merck Sharp & Dohme Corp. Process for preparing n-substituted hydroxypyrimidinone carboxamides
US8486975B2 (en) 2010-03-30 2013-07-16 Merck Canada Inc. Non-nucleoside reverse transcriptase inhibitors
US20130040914A1 (en) 2010-04-08 2013-02-14 Samson M. Jolly Prodrugs of an hiv reverse transcriptase inhibitor
JO3470B1 (ar) 2012-10-08 2020-07-05 Merck Sharp & Dohme مشتقات 5- فينوكسي-3h-بيريميدين-4-أون واستخدامها كمثبطات ناسخ عكسي ل hiv
RU2693622C2 (ru) 2014-04-01 2019-07-03 Мерк Шарп И Доум Корп. Пролекарственные средства ингибиторов обратной транскриптазы вич

Also Published As

Publication number Publication date
GT201500088A (es) 2017-09-28
CL2015000880A1 (es) 2015-08-28
KR101696128B1 (ko) 2017-01-13
US20170349585A1 (en) 2017-12-07
JP2015533123A (ja) 2015-11-19
DK3656384T3 (da) 2022-04-19
CN104822670A (zh) 2015-08-05
PL3656384T3 (pl) 2022-04-04
UA114006C2 (xx) 2017-04-10
JO3470B1 (ar) 2020-07-05
AP2015008355A0 (en) 2015-04-30
CA2887312C (en) 2017-02-28
PE20151787A1 (es) 2015-12-03
LT3295942T (lt) 2020-02-10
RS63112B1 (sr) 2022-05-31
TN2015000106A1 (en) 2016-06-29
CY1125202T1 (el) 2024-02-16
DOP2015000082A (es) 2015-08-16
HUE058903T2 (hu) 2022-09-28
US10189831B2 (en) 2019-01-29
TWI538907B (zh) 2016-06-21
EA201590674A1 (ru) 2016-02-29
AU2013329552B2 (en) 2016-09-15
LT2903977T (lt) 2017-12-11
US20160145255A1 (en) 2016-05-26
LT3656384T (lt) 2022-05-10
NZ706729A (en) 2018-09-28
DK3295942T3 (da) 2020-02-10
EP2903977A1 (en) 2015-08-12
EP3656384A1 (en) 2020-05-27
RS56543B1 (sr) 2018-02-28
JP2016128470A (ja) 2016-07-14
PL3295942T3 (pl) 2020-05-18
SI3295942T1 (sl) 2020-03-31
EP3656384B1 (en) 2022-02-23
TWI598343B (zh) 2017-09-11
IL238090B (en) 2019-02-28
HRP20171819T1 (hr) 2017-12-29
CY1122585T1 (el) 2021-01-27
PH12015500764B1 (en) 2015-07-27
GEP20186838B (en) 2018-04-10
BR112015007742B1 (pt) 2021-01-19
BR112015007742A2 (pt) 2017-08-08
HRP20200158T1 (hr) 2020-08-07
CO7350655A2 (es) 2015-08-10
PL2903977T3 (pl) 2018-01-31
EP3295942B1 (en) 2019-11-20
CN104822670B (zh) 2018-01-12
NI201500048A (es) 2016-06-29
MX2015004448A (es) 2016-02-17
MX355040B (es) 2018-03-28
RS59863B1 (sr) 2020-03-31
ECSP15018618A (es) 2019-06-30
CY1119655T1 (el) 2018-04-04
HUE048670T2 (hu) 2020-08-28
TW201623256A (zh) 2016-07-01
ES2770774T3 (es) 2020-07-03
PT2903977T (pt) 2017-11-14
HK1252786A1 (zh) 2019-05-31
SG11201502620UA (en) 2015-05-28
WO2014058747A1 (en) 2014-04-17
MY192716A (en) 2022-09-05
CR20150183A (es) 2015-08-10
DK2903977T3 (en) 2017-12-04
ME02918B (me) 2018-10-20
EA033436B1 (ru) 2019-10-31
MD4625B1 (ro) 2019-04-30
US20140100231A1 (en) 2014-04-10
PT3295942T (pt) 2020-02-18
US9469634B2 (en) 2016-10-18
EP3295942A1 (en) 2018-03-21
MD4625C1 (ro) 2019-11-30
PH12015500764A1 (en) 2015-07-27
ES2645638T3 (es) 2017-12-07
JP6097422B2 (ja) 2017-03-15
MA37959A2 (fr) 2017-12-29
TW201420576A (zh) 2014-06-01
EP2903977B1 (en) 2017-09-20
HUE037231T2 (hu) 2018-08-28
AR092876A1 (es) 2015-05-06
SI2903977T1 (sl) 2017-12-29
SI3656384T1 (sl) 2022-05-31
KR20150065186A (ko) 2015-06-12
JP5877281B2 (ja) 2016-03-02
CA2887312A1 (en) 2014-04-17
MD20150047A2 (ro) 2015-08-31
BR112015007742B8 (pt) 2021-03-23
AU2013329552B8 (en) 2017-01-12
AU2013329552A1 (en) 2015-04-16
ES2909190T3 (es) 2022-05-05
NO2903977T3 (zh) 2018-02-17
HRP20220502T1 (hr) 2022-05-27
US9718819B2 (en) 2017-08-01
ZA201503143B (en) 2016-06-29
PT3656384T (pt) 2022-03-22
AU2013329552C1 (en) 2016-12-22

Similar Documents

Publication Publication Date Title
HK1207369A1 (zh) -苯氧基- -嘧啶- -酮衍生物及其用作 逆轉錄酶抑制劑
HRP20151103T1 (en) Substituted triazolopyridines and their use as ttk inhibitors
EP2931730A4 (en) 4-PYRIDINONETRIAZINE DERIVATIVES AS INHIBITORS OF HIV INTEGRASE
EP2828258A4 (en) NOVEL PYRIDOPYRIMIDINE DERIVATIVES AND THEIR USE
ZA201303433B (en) Inhibitors of hiv replication
HK1198433A1 (zh) -酰基二肽衍生物及其應用
HK1208453A1 (zh) 取代的吡啶並嘧啶化合物及其作為 抑制劑的用途
EP2772480A4 (en) HIV REPLICATION INHIBITORS
HK1206264A1 (zh) 犬尿氨酸- -單加氧酶抑制劑、其藥物組合物及其使用方法
EP2952503A4 (en) HIV REPLICATION INHIBITORS
EP2877469A4 (en) SUBSTITUTED NAPHTHYRIDINEDIONE DERIVATIVES AS INHIBITORS OF HIV INTEGRASE
EP2986291A4 (en) COMPOUNDS DERIVED FROM 4-PYRIDONE AND USES THEREOF AS INHIBITORS OF HIV INTEGRASE
HK1198833A1 (zh) -酰基肽衍生物及其應用
IL228433A0 (en) Pyridopyrazine history and their use
HK1206350A1 (zh) -咪唑- -胺化合物及其作為 抑制劑的用途
ZA201503466B (en) Phenothiazine derivatives and their use against tuberculosis
ZA201401330B (en) Hiv replication inhibitors
SG11201501212QA (en) Quinazoline derivatives and uses thereof as apoptosis inhibitor
EP2939668A4 (en) PDK4 INHIBITOR AND USE THEREOF
PT2978763T (pt) Derivados de 2-cetoamida como inibidores da ligação do vih
GB201215414D0 (en) Composition and use